Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Feb. 05, 2024 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core […]
Intuitive Machines Lunar Lander Encapsulated and Scheduled for Launch
HOUSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines”) (“Company”), a leading space exploration, […]
J&J Snack Foods Reports Fiscal 2024 First Quarter Revenue of $348.3M and Net Earnings Growth of 9.8%
MOUNT LAUREL, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) — J&J Snack Foods Corp. (NASDAQ: JJSF) (the “Company”) today reported financial […]
Casella Waste Systems, Inc. to Host Conference Call on Its Fourth Quarter 2023 Results
RUTLAND, Vt., Feb. 05, 2024 (GLOBE NEWSWIRE) — Casella Waste Systems, Inc. (Nasdaq: CWST), a regional solid waste, recycling, and […]
Oportun Appoints Two New Independent Members to its Board of Directors
SAN CARLOS, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — Oportun (Nasdaq: OPRT) today announced the addition of two new independent […]
FinWise Bancorp Announces Two Senior Leadership Promotions
– Promotes Robert Keil and Richard Thiessens to Executive Vice Presidents –– Highlights Company’s Commitment to Delivering on Strategic Initiatives […]
NXP Semiconductors Reports Fourth Quarter and Full-Year 2023 Results
EINDHOVEN, The Netherlands, Feb. 05, 2024 (GLOBE NEWSWIRE) — NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the […]
SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving […]
ThredUp to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
OAKLAND, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) — ThredUp (NASDAQ: TDUP, LTSE: TDUP), one of the largest online resale platforms […]
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected […]
